🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Liquid Biopsy-Based Early Screening for Endometrial Cancer in Regional Chinese Populations

Recruitingn/aAges any - 18 YearsFemaleGuizhou Provincial People's Hospital
NCT07892755 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Endometrial cancer is one of the most common gynecological malignancies, and its incidence is rising. Currently, there is a lack of highly effective and non-invasive screening methods. Liquid biopsy, which analyzes cell-free DNA (cfDNA) in the blood, has emerged as a promising approach for early cancer detection. This observational study aims to develop and evaluate a non-invasive blood test to screen for early-stage endometrial cancer and to distinguish between benign and malignant endometrial lesions. This study plans to enroll 512 female participants, divided into three groups: 216 patients with stage I-IV endometrial cancer, 80 patients with atypical endometrial hyperplasia (a precancerous condition), and 216 healthy controls. We will collect peripheral blood samples from all participants and perform low-pass whole-genome sequencing (WGS) on the extracted plasma cfDNA. By analyzing

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Female, aged \> 18 years. Participants fully understand the study requirements and sign the written informed consent. Cohort A (Endometrial Cancer): Patients with histologically and/or cytologically confirmed stage I-IV endometrial cancer; comprehensive clinical and pathological information is available. Cohort B (Atypical Hyperplasia): Patients diagnosed with atypical endometrial hyperplasia; comprehensive clinical and pathological information is available. Cohort C (Healthy Control): Healthy female subjects with no tumors or suspicious nodules confirmed by systematic examination. Exclusion Criteria: * Pregnant women. Current diagnosis of tumors other than endometrial cancer or a history of previous tumors. Received any form of tumor treatment prior to blood draw, including surgery, radiotherapy/chemotherapy, endocrine therapy, targeted therapy, or immunotherapy. Current febrile illness, or acute/inflammatory disease requiring internal medical treatment within 14 days prior to blood draw. Organ transplant recipients or previous recipients of allogeneic bone marrow or stem cell transplants. Poor health status or unsuitable for blood draw. Any other clinically significant disease or condition that, in the investigator's opinion, may affect protocol compliance, affect the subject's ability to sign informed consent, or make the subject unsuitable for this clinical study.
💊

What it tests

  • Not listed
📍

Where

1 site
Guizhou Provincial People's Hospital
Guiyang, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy